胶质母细胞瘤组织中TRAIL受体表达的研究

Study on expression and significance of TRAIL-R in human glioblastoma

目的研究TRAIL受体(TRAIL receptor,TRAIL-R)在胶质母细胞瘤中的表达,并探讨其临床意义。方法联合采用免疫组织化学和RT-PCR方法检测胶质母细胞瘤及正常脑组织中TRAIL-R的表达。结果25例胶质母细胞瘤均表达死亡受体(death receptor,DR)4和DR5,11例(44.0%)表达诱骗受体(decoy receptor,DcR)1,5例(20.0%)表达DcR2,而20例正常脑组织普遍表达DcR1和DcR2。胶质母细胞瘤组织中DR的高表达以及DcR的低表达不同于正常脑组织中DR的低表达及DcR的高表达,两者间差异有显著性(P<0.01)。RT-PCR显示,25例胶质母细胞瘤组织分别有22例(88.0%)DcR1和15例(60.0%)DcR2在mRNA水平呈阳性表达,DcR在转录水平的表达明显高于翻译水平(P<0.01)。结论胶质母细胞瘤中普遍存在DR的高表达和DcR的低表达,DcR在胶质母细胞瘤中限制性表达的调控位于转录后水平。这可能为胶质母细胞瘤的凋亡诱导治疗提供新的靶点和策略。

[Objective ] To investigate the expression and significance of TRAIL-R in human glioblastoma. [Methods] The expression of TRAIL-R was determined by immunohistochemistry and RT-PCR in 25 samples of glioblastoma and 20 samples of normal brain tissue. [Results] With low DcR expression in partial glioblastoma cells and low DR expression in partial normal brain cells, DR was highly expressed in all glioblastoma samples while DcR in most normal brain tissue. High DR expression and low DcR expression in glioblastoma tissue differed from low DR expression and high DcR expression in normal brain tissue （P 〈0.01）. There was significant difference between the DcR expression in mRNA level and that in protein level （P 〈0.01）. [Conclusions] High DR expression and low DcR expression are prevalent in glioblastoma tissue. The control of DcR expression maybe lay in protein level. It contributes to the apoptosis-inducing therapy of glioblastoma.